23 results about "Progestogen" patented technology

The invention discloses a chemiluminescence immunoassay method and kit for detecting progestational hormone of pandas, and belongs to the technical field of biological detection. The specific process comprises the following steps: by taking goat anti-mouse IgG as a coating antibody, enabling a progestational hormone standard substance or a to-be-detected sample and horse radish peroxidase labeled progestational hormone to compete with a limited amount of progestational hormone antibodies together; after incubation and washing, a chemiluminescent substrate is added, and quantitative analysis of the progestational hormone in the panda urine or excrement is realized by detecting the intensity of a luminescent signal according to a standard curve. The invention provides a novel chemiluminescence immunoassay method, the sensitivity of the chemiluminescence immunoassay method is far higher than that of a traditional ELISA method (the lowest detection line can reach 31.25 pg / mL), the operation is simple and convenient, the detection is rapid, and the urgent demand on rapid and accurate determination of the hormone level in panda pregnancy monitoring and reproduction management can be met.

The application relates to the technical field of animal models, in particular to a modeling method and an evaluation method of an animal menstrual dysmenorrhea model and application, wherein the animal with removed ovaries is injected with estrogen, progesterone and oxytocin, the pharmacological injection of progesterone can reduce the harm and mortality rate of the animal caused by the implantation and removal of a progesterone release body in the prior art, the surgical stress of the animal is reduced, the injection time of the progesterone in the application is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with the non-menstrual process of the dysmenorrhea model in the prior art, the animal menstrual dysmenorrhea model can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment, and effectively help patients to relieve pain.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

The invention relates to a method for simultaneously detecting various steroid hormones in serum, which comprises the following steps: extracting hormones in serum by a liquid-liquid extraction method; a derivatization reagent is added into the extracted hormone, an oximation reaction is carried out, and the derivatization reagent comprises quaternary ammonium oxygen amine; the hormone after oximation reaction is injected into a two-dimensional liquid chromatography-tandem mass spectrometry system for detection, the hormone is enriched on a one-dimensional chromatographic column, and then the enriched hormone is subjected to back flushing and transferred to a two-dimensional chromatographic column for analysis. According to the method, the backwashing transfer two-dimensional liquid chromatography-tandem mass spectrometry and the derivatization reaction are combined, various steroid hormones including progestational hormone and androgen can be detected at the same time, and the method has the advantage of being high in detection sensitivity.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to sublingual lozenges of progesterone and analogues thereof as well as a preparation method and application of the sublingual lozenges. Specifically, a novel sublingual administration dosage form which is more suitable for being absorbed by a human body is designed according to physicochemical properties of progesterone and analogues thereof. The sublingual lozenge is composed of a main drug, a filler, a disintegrating agent, a mucous membrane promoter, a flavoring agent, a lubricant and the like. The sublingual lozenge is quickly disintegrated under the action of saliva, is quickly absorbed through tongue mucosa, takes effect quickly, avoids the first-pass effect, improves the bioavailability, and is suitable for various clinical scenes needing quick and efficient progestational hormone support.

The invention provides a chemical synthesis method of 20 alpha-hydroxyprogesterone, and belongs to the technical field of organic synthesis. The invention provides a simple and efficient synthesis path, and high-purity 20 alpha-hydroxyprogesterone can be obtained with good yield and extremely high stereoselectivity and specificity. The method is easy and convenient to operate and good in reproducibility, and effectively overcomes the defects that a product is an isomer mixture, separation and purification are difficult, and the target product yield is low in a traditional method. The successful implementation of the invention provides a stable and reliable material source for obtaining sufficient high-purity 20 alpha-hydroxyprogesterone, powerfully supports the subsequent activity research, dosage form development and new drug creation of the compound, and has important significance in the field of health drugs for women, health protection and health protection. The compound shows important application value and potential in the field of research and development of novel progesterone drugs.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

The present application belongs to the technical field of natural polymer materials, and particularly relates to a purified polysaccharide of Rhizoma Polygonati, a preparation method thereof and application of the purified polysaccharide in preparation of a medicine for relieving mammary gland hyperplasia. The purified polysaccharide of Rhizoma Polygonati comprises xylose, mannose, glucose and galactose, and the molar ratio of the xylose, mannose, glucose and galactose is 6.45:30.26:7.43:55.87. The molecular weight distribution of the purified polysaccharide of Rhizoma Polygonati is within 2000-30000 Da, and the molecular weight is concentrated at 22877 Da. The purified polysaccharide of Rhizoma Polygonati can reduce the toxic damage of estrogen and progesterone imbalance to HC11 mammary epithelial cells, and a low concentration of the purified polysaccharide of Rhizoma Polygonati can produce a protective effect on the cells. The purified polysaccharide of Rhizoma Polygonati is verified to have a significant inhibitory effect on mammary gland hyperplasia of mice through a mammary gland hyperplasia model intervention experiment, and therefore can be used for developing a medicine for treating mammary gland hyperplasia.

The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones. The present invention also relates to a method of preparing the microspheres that control the release of the progestogen hormone and methods of using the microspheres that control the release of the progestogen hormone to treat conditions such as pregnancy and fertility in women as well as gynecological disorders such as secondary amenorrhea, endometriosis, abnormal uterine bleeding due to hormonal imbalance, and acne.

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

The invention relates to a traditional Chinese medicine effective component screening method based on a chemical fingerprint spectrum and multi-omics combined analysis. The method comprises the following steps: preparing a semen cuscutae-fructus lycii medicine pair extract and establishing a UPLC-Q-TOF-MS / MS chemical fingerprint spectrum; detecting the levels of estradiol, luteinizing hormone, anti-mullerian hormone and follicle-stimulating hormone in the premature ovarian insufficiency animal model; screening characteristic components related to the drug effect through multivariate statistical analysis; performing transcriptome sequencing on the ovarian tissue, and combining GO / KEGG analysis to determine a key pathway; integrating database prediction targets and differential genes, screening hub genes and constructing a protein interaction network; and finally verifying the binding activity of the candidate component and the core target protein through molecular docking and molecular dynamics experiments. According to the invention, systematic screening and action mechanism analysis of drug effect related components are realized, and a new technical approach is provided for mass marker determination and estrogen simulating action research of the dodder-wolfberry drug pair.

This document offers estrogen and progesterone replacement therapies. These include, among others, the following formulations: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.

The present invention provides methods of female contraception, the methods comprising administering an effective amount of a combination of a progesterone receptor agonist and a cyclooxygenase-2 inhibitor in each of two doses, the first dose is administered within about 24 hours before or after a first act of sexual intercourse and the second dose is administered between about 36 hours and about 60 hours after the first dose.

A method for providing progestogen only contraception. The method includes the step of orally administering once a day to a subject desiring contraception a dosage form comprising about 0.125 mg to about 0.145 mg of levonorgestrel (LNG) and at least one pharmaceutically acceptable excipient for a period of at least 23 to 30 days or longer.

The invention provides application of RELN in preparation of a medicine for preventing, relieving and / or treating ovarian aging diseases. The invention finds that RELN specifically secreted by lymphatic endothelial cells (LECs) is a key factor for regulating and controlling ovarian functions for the first time, and the expression level of the RELN is obviously reduced along with ovarian aging. In-vitro experiments prove that the proliferation activity and hormone secretion function of human and mouse granular cells can be remarkably enhanced by applying the RELN recombinant protein. In an ovarian aging mouse model, overexpression of the RELN in the ovarian can safely and effectively improve the levels of serum estrogen, progestational hormone and anti-mullerian hormone (AMH), increase the reserve of healthy follicles in the ovarian and reduce atresia follicles. Therefore, the RELN provides a brand-new target spot and strategy for developing medicines (such as protein preparations, gene therapy products or agonists) for delaying ovarian aging.

The invention provides an application of an IGFBP5 (Insulin-like Growth Factor Binding Protein 5) gene in preparation of a medicine for improving endometrial receptivity impairment, and the IGFBP5 gene is used for preparing the medicine for improving the endometrial receptivity impairment. The number of embryo implantation sites can be effectively increased, abnormal proliferation of endometrial epithelial cells is reduced, and the relative expression level of estrogen response genes and progestational hormone response genes is improved. The IGFBP5 gene disclosed by the invention is a key downstream effector molecule of an IL-22-STAT3 signal channel, and the endometrial receptivity can be enhanced by supplementing IGFBP5 protein so as to save embryo implantation failure.

The application discloses a use of a HOTAIR-PRC2 blocking agent combined with a progestogen in preparation of a drug for conservation treatment of endometrial cancer. The application provides a use of a HOTAIR-PRC2 specific blocking agent combined with a progestogen, which can synergistically inhibit the progression of endometrial cancer. The HOTAIR-PRC2 specific blocking agent provided by the application can restore the expression of PR, and the combination of the progestogen can synergistically inhibit the proliferation, invasion and migration of tumors, promote cell apoptosis, block the cell cycle, and enhance the treatment effect of the progestogen, thereby providing a new treatment idea for the conservation treatment of endometrial cancer.

The invention discloses a construction method and application of an endometrial cancer progestational hormone drug-resistant cell strain based on CALB1 knockdown, it is found through sequential multi-omics dynamic analysis that CALB1 is continuously reduced in the drug-resistant process, the cell strain with the gene knocked down is constructed with the CALB1 as a target gene, and the cell strain has higher IC50 for progestational hormone, and the cell strain has a good anti-tumor effect on progestational hormone. The drug-resistant phenotype is stably maintained for more than 20 generations, the standardized requirements of mechanism research and drug screening are met, and the method has a remarkable application prospect.

The present invention provides a method and composition for reversibly localizing proteins to the outer portion of the cell surface. [Solution] Essentially, the protein must include a hormone receptor such as estrogen receptor alpha or progesterone receptor in addition to the transmembrane domain. The compositions provided herein may include nucleic acids encoding the polypeptide of interest and the ligand-binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.